Shopping Cart
- Remove All
Your shopping cart is currently empty
ATR-IN-29
😃Good
Catalog No. T79121Cas No. 2761193-67-1
ATR-IN-29, a potent, orally active inhibitor of ATR kinase, exhibits an IC50 of 1 nM and demonstrates antiproliferative activity [1].
ATR-IN-29
😃Good
Catalog No. T79121Cas No. 2761193-67-1
ATR-IN-29, a potent, orally active inhibitor of ATR kinase, exhibits an IC50 of 1 nM and demonstrates antiproliferative activity [1].
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | Inquiry | 8-10 weeks | |
| 50 mg | Inquiry | 8-10 weeks |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "ATR-IN-29"
Elimusertib
BAY-1895344
T73181876467-74-1
Elimusertib (BAY-1895344) is a potent, highly selective, and orally available ATR inhibitor with an IC50 of 7 nM, demonstrating significant anti-tumor efficacy as a monotherapy and strong combination potential with targeted alpha therapy Radium-223 dichloride.
- $31
Size
QTY
GJ103 sodium salt
T42511459687-96-7
GJ103 sodium salt is an active analog of GJ072, a read-through compound. It has been shown to reduce the surface tension of aqueous solutions, which makes it easier for molecules to move through the solution. It has also been shown to reduce the viscosity of aqueous solutions, which makes it easier for molecules to move through the solution. Additionally, it has been shown to reduce the pH of aqueous solutions, which can have a variety of effects on the biochemical and physiological processes of living organisms.
- $42
Size
QTY
Schisandrin B
Wuweizisu-B, Schizandrin B, Schisandrin B (Sch B), gamma-Schisandrin
T292561281-37-6
Schisandrin B (Schisandrin B (Sch B)) has an antioxidant effect on rodent liver and heart.
- $35
Size
QTY
Berzosertib
VX-970, VE-822
T26691232416-25-9
Berzosertib (VE-822) is an ATR inhibitor (Ki<0.2 nM) that also inhibits ATM (Ki=34 nM). Berzosertib has antitumor activity and has been used in trials investigating the treatment of ovarian tumors, plasmacytoid tumors of the ovary, solid tumors in adults, advanced solid tumors, and advanced solid tumors.
- $30
Size
QTY
Ceralasertib
Cited
AZD6738
T33381352226-88-0
Ceralasertib (AZD6738) is an orally active, selective ATR kinase inhibitor with an IC50 of 1 nM.
- $43
Size
QTY
CitedDactolisib Cited
NVP-BEZ235, BEZ235
T2235915019-65-7
Dactolisib (BEZ235) is an orally bioavailable inhibitor of PI3K and mTOR, with IC50 values of 4 nM for p110α, 5 nM for p110γ, 7 nM for p110δ, 75 nM for p110β, and 20.7 nM for mTOR.
- $39
Size
QTY
CitedNU6027
T6612220036-08-8
NU6027 is a potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with Ki of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.
- $37
Size
QTY
CP-466722
CP466722, CP 466722
T62611080622-86-1
CP-466722, an effective and reversible ATM inhibitor, does not inhibit ATR and PI3K or PIKK family members in cells.
- $30
Size
QTY
(Z)-Mirin
Mirin
T31341198097-97-0
(Z)-Mirin is a potent Mre11–Rad50–Nbs1 (MRN) complex inhibitor, and inhibits Mre11-associated exonuclease activity.
- $50
Size
QTY
KU60019 Cited
KU-60019, KU 60019
T2474925701-49-1In house
Ku-60019 is a potent, reversible inhibitor of ATM kinase (IC50: 6.3 nM). It is much less effective or without effect against a panel of 229 other kinases.
- $48
Size
QTY
CitedAZ32 Cited
T44432288709-96-4
AZ32 is an orally bioavailable, blood-brain barrier-penetrating ATM inhibitor with an IC50 of <6.2 nM for the ATM enzyme and an IC50 of 0.31 μM for ATM in cells.
- $51
Size
QTY
CitedRo 90-7501
RO-90-7501
T16773293762-45-5In house
Ro 90-7501 is an amyloid β42 (Aβ42) protofibrillar and TPR-dependent PP5 inhibitor, a novel radiosensitizer for cervical cancer cells, which inhibits ATM phosphorylation, promotes apoptosis, and induces cell-cycle arrest. Ro 90-7501 also exhibits antiviral activity and potential anticancer activity by inhibiting ATM phosphorylation and DNA repair, and by inhibiting HCMV.
- $30
Size
QTY
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | ATR-IN-29, a potent, orally active inhibitor of ATR kinase, exhibits an IC50 of 1 nM and demonstrates antiproliferative activity [1]. |
| Targets&IC50 | ATR:1 nM |
| In vitro | ATR-IN-29 (compound 1) exhibited antiproliferative activity over 4 days, with IC50 values of 156.70, 38.81, 22.48, 181.60, and 19.02 nM against A549, HCC1806, HCT116, OVCAR-3, and NCI-H460 cell lines, respectively [1]. |
| In vivo | ATR-IN-29 administered at a dose of 10 mg/kg orally once demonstrated favorable pharmacokinetic parameters in CD-1 (ICR) mice, with a half-life (t1/2) of 1.64 hours, a maximum concentration (Cmax) of 9343 ng/mL, and an area under the curve from time zero to the last measurable concentration (AUC 0-t) of 98507 ng·h/mL, as well as an area under the curve from time zero to infinity (AUC 0-inf) of 98517 ng·h/mL. |
| Molecular Weight | 378.43 |
| Formula | C19H22N8O |
| Cas No. | 2761193-67-1 |
Storage & Solubility Information
| Storage | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy ATR-IN-29 | purchase ATR-IN-29 | ATR-IN-29 cost | order ATR-IN-29 | ATR-IN-29 chemical structure | ATR-IN-29 in vivo | ATR-IN-29 in vitro | ATR-IN-29 formula | ATR-IN-29 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.